S2 Ep8: AI Discoverability Is a Leadership Problem - Not a Content One

Most life science companies haven't checked whether AI recommends them. The ones that have are already pulling ahead.

In this episode, Matt Wilkinson and Jasmine Gruia-Gray dig into the real commercial stakes of AI search visibility for life science tools and diagnostics companies - cutting through the AEO/GEO hype to ask the harder question: who in your organisation actually owns this?

This episode is for: Marketing leaders, commercial directors, and CEOs at life science tools, diagnostics, and biotech companies who want to understand what AI discoverability actually means for pipeline and brand - and why it's a leadership problem, not a content one.

KEY IDEA: AI discoverability is a leadership mandate, not a content strategy problem.

What you will learn:

• Why 62% of life science exhibitors have never run the basic AI visibility test - and what that means commercially
• The citation compression dynamic: AI surfaces roughly five brands per B2B category, and that list is hardening now
• Why absence from AI recommendations is categorically different from ranking fifth on Google
• The structural AI citation advantage life science companies hold - and why most can't access it
• Why framing this as a content project guarantees you hit a ceiling
• What the organisations that win will have in common: a named leader with cross-functional authority

Keywords: AI discoverability, life science marketing, AEO, GEO, answer engine optimisation, citation compression, AI search, B2B life science, biotech marketing, AI visibility, LLM search, AI overviews

Watch the full episode, subscribe to A Splice of Life Science Marketing, and explore Strivenn's AI readiness resources at strivenn.com.